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Reactive oxygen speciesAnoikis is a programmed cell death inducedupon cell detachment from extracellularmatrix, behaving as a critical
mechanism in preventing adherent-independent cell growth and attachment to an inappropriate matrix, thus
avoiding colonizing of distant organs. As anchorage-independent growth and epithelial–mesenchymal transi-
tion, two features associatedwith anoikis resistance, are vital steps during cancer progression andmetastatic col-
onization, the ability of cancer cells to resist anoikis has now attracted main attention from the scientiﬁc
community. Cancer cells develop anoikis resistance due to several mechanisms, including change in integrins'
repertoire allowing them to grow in different niches, activation of a plethora of inside-out pro-survival signals
as over-activation of receptors due to sustained autocrine loops, oncogene activation, growth factor receptor
overexpression, or mutation/upregulation of key enzymes involved in integrin or growth factor receptor
signaling. In addition, tumor microenvironment has also been acknowledged to contribute to anoikis resistance
of bystander cancer cells, by modulating matrix stiffness, enhancing oxidative stress, producing pro-survival
soluble factors, triggering epithelial–mesenchymal transition and self-renewal ability, as well as leading to
metabolic deregulations of cancer cells. All these events help cancer cells to inhibit the apoptosis machinery
and sustain pro-survival signals after detachment, counteracting anoikis and constituting promising targets for
anti-metastatic pharmacological therapy. This article is part of a Special Section entitled: Cell Death Pathways.
Guest Editors: Frank Madeo and Slaven Stekovic.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
In the absence of attachment to extracellular matrix (ECM) or
upon cell adhesion to inappropriate location, cells undergo a particu-
lar type of apoptosis, termed anoikis, a Greek word meaning loss of
“home” or “homelessness”. Indeed, integrin receptors, as mediatorse; ECM, extracellular matrix;
lial–mesenchymal transition;
hibitory protein; FAK, focal ad-
hepatocyte growth factor; HIF,
inked kinase; IKK, IκB kinase;
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rights reserved.of cell–ECM interaction, not only provide physical links with the cyto-
skeleton but also transduce signals from the ECM to the cell, manda-
tory for several cellular processes including migration, proliferation
and survival [24,71,72,84,180]. Anoikis, ﬁrst described in epithelial
and endothelial cells [71], can be viewed as a physiologically relevant
process which ensures development and tissue homeostasis. Anoikis
acts as an important defense for the organism by preventing detached
cells' re-adhesion to new matrices in incorrect locations and their
dysplastic growth. As a result, failure to execute the anoikis program
could result in adherent cells surviving under suspension conditions
or proliferating at ectopic sites where the ECM proteins are different
from the original ones. This deregulation in anoikis execution is
emerging as a hallmark of cancer cells and contributes to the forma-
tion of metastasis in distant organs [47,73,92,217].
2. Molecular pathways of anoikis
The initiation and execution of anoikis ismediated by different path-
ways, all of which terminally converge into the activation of caspases
and downstream molecular pathways, culminating in the activation of
endonucleases, DNA fragmentation and cell death. The induction of
the anoikis programoccurs through the interplay of two apoptotic path-
ways, namely the perturbation of mitochondria (the intrinsic pathway)
or the triggering of cell surface death receptors (the extrinsic pathway)
[92,98] (Fig. 1). The proteins of the Bcl-2 family are key players of both
Fig. 1. Extrinsic and intrinsic apoptotic pathways. The lack of ECM contact or the engagement with inappropriate ECM leads to the activation of anoikis from death receptors
(extrinsic pathway) and mitochondria (intrinsic pathway). In the extrinsic pathway of apoptosis, caspase-8 is activated upon engagement of death receptors (i.e., Fas or TNFR1),
leading to cleavage and activation of executioner caspases (for example, caspase-3). In the intrinsic pathway, Bax/Bak activation is promoted by BH3-only proteins, such as Bim,
Bad, Bik, Puma, Hrk, Bmf and Noxa. Among them, Bid and Bim (activators), directly promote the assembly of Bax–Bak oligomers, while the others BH3-only members (sensitizers),
counteract the anti-apoptotic functions of Bcl-2, thus indirectly inducing Bax/Bak activation. As a ﬁnal outcome, cytochrome c is released to the cytoplasm, where it induces the
formation of the apoptosome, leading to activation of executioner caspases.
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(i) the anti-apoptotic proteins, including Bcl-2, Bcl-XL and myeloid
cell leukemia sequence 1 (Mcl-1); (ii) the multidomain pro-apoptotic
proteins Bax, Bak and Bok; and (iii) the pro-apoptotic BH3-only
proteins, counting Bid, Bad, Bim, Bik, Bmf, Noxa, Puma and Hrk [180].
2.1. The intrinsic pathway
The intrinsic pathway is triggered in response to several intracel-
lular signals, including DNA damage and endoplasmic reticulum
stress, where mitochondria play a central role with regard to the con-
trol of apoptosis [132]. In response to death signals, the pro-apoptotic
protein Bax and Bak translocate from the cytosol to the outer mito-
chondrial membrane (OMM), where their oligomerization creates a
channel within the OMM, causing mitochondrial permeabilization
and cytochrome c release. In addition to the intrinsic pore forming ac-
tivity of the Bax proteins, membrane permeabilization may result
even from their interaction with mitochondrial channel proteins
such as the voltage-dependent anion channels [206]. The release of
cytochrome c leads to the formation of the so-called “apoptosome”,
composed of caspase-9, the cofactor apoptosis protease activating
factor (Apaf) and cytochrome c, with subsequent activation of the ef-
fector caspase-3 and execution of the apoptotic process [48,224,266].
The pro-apoptotic BH3-only proteins act as critical players during
the intrinsic cascade of the anoikis program [25]. Among the members
of this family, Bid and Bim are activated following detachment of cells
from ECM and rapidly promote the assembly of Bax–Bak oligomers
within OMM. These members of the BH3-only protein family are
termed “activators” [221]. In particular, Bim is sequestered in thedynein cytoskeletal complexes until cell detachment induces release
of Bim from these structures and causes its translocation to the mito-
chondria [45]. Loss of cell adhesion also causes Bim accumulation,
through the inhibiting of its proteasomal degradation initiated by an ex-
tracellular signal-regulated kinase (ERK) and phosphoinositide-3-OH
kinase (PI3K)/Akt-mediated phosphorylation of Bim, elicited upon
integrin engagement [45,138,176].
Another group of the BH3-only proteins are termed “sensitizers”
and includes Bad, Bik, Bmf, Noxa, Puma and Hrk. The sensitizer
BH3-only proteins are unable to directly activate Bax and Bak oligo-
merization and contribute to cell death through the inactivation of
the anti-apoptotic functions of Bcl-2, by competing for its BH3 bind-
ing domain, thus freeing activator BH3-only proteins to induce Bax–
Bak oligomer formation [14,135,140,231]. Indeed, Bcl-2 is the master
anti-apoptotic member of the family which avoids mitochondrial dys-
function and prevents apoptosis both by interacting with Bak/Bax ap-
optotic members, thus avoiding their clustering into pores and by
sequestering the activator members of the BH3-only proteins, namely
Bid and Bim, thereby preventing Bak/Bax oligomerization [79,231].
Compelling evidence indicate the involvement of other members of
the BH3-only family in anoikis execution of different cell histotypes. For
example, Noxa and Puma are transcriptionally regulated by p53 and
have been implicated in ﬁbroblast anoikis [162,203]. Furthermore, in
epithelial cells the Bcl-2 modifying factor (Bmf) behaves as a sentinel
able to register damage at the cytoskeleton and to convey death signals.
Indeed, upon cell detachment, Bmf is released from its previous interac-
tion with the myosin V motor complex [175] and accumulates in the
mitochondria, where it neutralizes Bcl-2, leading to cytochrome c re-
lease and anoikis execution [203].
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Alongside the intrinsic pathway, extrinsic pathway also contrib-
utes to anoikis execution. The extrinsic pathway is initiated by ligand
binding of members of the tumor necrosis factor receptor (TNFR) su-
perfamily of death receptors, such as Fas receptor, TNFR1 and the
TNF-related apoptosis inducing ligand (TRAIL) receptor-1 and -2,
resulting in the formation of the death-inducing signaling complex
(DISC). In turn, DISC, via the interaction with adaptor proteins such
as the Fas-associated death domain protein (FADD), recruits several
molecules of caspase-8, thereby promoting their activation. Active
caspase-8 is then released to the cytoplasm where it cleaves and acti-
vates the effectors caspase-3, -6, and -7, culminating in substrate pro-
teolysis and cell death [221,235]. Alternatively, caspase 8 activation
results in the cleavage and activation of Bid, which in its truncated
form (t-Bid), can promote mitochondrial cytochrome c release and
assembly of the apoptosome, thus linking the extrinsic pathway to
the intrinsic one [230]. Recent evidence reported that upon cell de-
tachment from ECM, a mitochondrial protein, named Bit1, is released
to the cytoplasm and acts as a pro-apoptotic mediator, inducing a
caspase-independent form of apoptosis [117,119]. In some instances,
activation of the death receptor pathway could be secondary to mito-
chondrial damage, establishing once again a crosstalk between ex-
trinsic death signals and the intrinsic pathway [188]. Previous
studies demonstrated that the loss of anchorage to ECM leads to the
upregulation of Fas and Fas ligand and a concomitant downregulation
of FLICE inhibitory protein (FLIP), an endogenous inhibitor of
Fas-mediated signaling, indicating the important role of the extrinsic
pathway to the anoikis process [4,183]. Interestingly, also changes in
cell shape can induce extrinsic anoikis [41]. Indeed, cell rounding fol-
lowing detachment could lead to “induced proximity” of Fas recep-
tors resulting in their activation [161].
As described above, both extrinsic and intrinsic apoptotic pathways
merge at and rely on the activation of the effector caspase-3, which ini-
tiates a downstream proteolytic cascade to effect cell death. In particu-
lar, cleavage of signalingmolecules like focal adhesion kinase (FAK) and
p130Cas is important for the apoptotic execution [51,180,204,242]. The
caspase-mediated cleavage of FAK disrupts focal adhesion architecture
and inhibits its survival signal [1]. p130Cas, an SH2/SH3 adaptor pro-
tein, which binds FAK and transmits integrin signals, undergoes
caspase-mediated cleavage, thus impairing its subcellular localization
as well as its interaction with paxillin [204]. Moreover, p130Cas cleav-
age generates a C-terminal inhibitory fragment which impairs the tran-
scription of p21Waf1/Cip1, thus contributing to the apoptotic response
by blocking the cell cycle [130]. Disruption of the cytoskeleton, which
accompanies cell–matrix dissociation,may also contribute to anoikis in-
duction by releasing pro-apoptotic factors such as Bim [174] or death
receptors such as Fas [232] from a sequestered state.
3. Protection from anoikis in physiological conditions
3.1. Cell adhesion to ECM
Epithelial cells are protected by anoikiswhen they are adherent on
permissive ECM proteins. An enormous amount of literature estab-
lishes the central role of integrins in suppressing apoptosis in at-
tached cells by eliciting anti-apoptotic and pro-survival signals from
the ECM [72,85]. Integrins are categorized depending on their α or
β subunit composition. There at least four types of integrins (α5β1,
αvβ3, α1β1 and α6β1) acknowledged to play a role in cell survival
[29,154,163,261] in various cellular models. These speciﬁc integrins
have different abilities to protect cells from apoptosis and anoikis,
suggesting that they utilize diverse signaling pathways. Their down-
stream pathways or molecules are different and include FAK [75],
Src kinase [169], integrin-linked kinase (ILK) [22], PI3K/Akt [127]
and mitogen activated protein kinase (MAPK) [49] (Fig. 2). Activationor overexpression of these signaling molecules has been shown to in-
terfere with anoikis, and it is therefore not surprising that some of
these molecules have been found to be upregulated or activated in
malignant cells.
FAK is one of the most important integrin signaling molecules
recruited into focal adhesions upon cell–ECM contact, which affects
multiple critical cellular processes such as cell survival, proliferation,
motility, and differentiation. FAK is rapidly phosphorylated and acti-
vated following integrin-mediated adhesion. The autophosphoryl-
ation on Tyr397 recruits and activates Src, which in turn further
phosphorylates FAK in the activation loop, yielding the fully active
FAK enzyme [36,144]. The activated FAK enables the recruitment of
other scaffold and signaling molecules to the focal adhesion sites,
consequently activating the downstream cell survival signaling.
PI3K is one of the FAK-activated proteins, which in turn recruits
and activates its downstream target protein kinase B (PKB/Akt)
[42,247]. Akt activation promotes cell survival by several indepen-
dent mechanisms. For example, it prevents the release of cytochrome
c from mitochondria by phosphorylating the pro-apoptotic protein
Bad on Ser136 [53,54,56], causing the release of Bcl-2 and directly in-
hibits the caspase cascade by phosphorylating the procaspase-9 [38].
Akt can also activate the nuclear factor κB (NFκB) survival pathway
by phosphorylating and inhibiting IκB (the inhibitory subunit of
NFκB) through IκB kinase (IKK) [182].
The MAPK pathway is another signaling cascade triggered by FAK
activation. Several mechanisms are proposed to account for the link
between FAK and MAPK [190]. One is the Src-mediated phosphoryla-
tion of FAK on Tyr925, which creates a binding site for the Grb2 adap-
tor protein, leading to the activation of the MAPK pathway [192,194].
Another mechanism for MAPK activation is that the FAK/Src complex
promotes the tyrosine phosphorylation of Shc, which in turn leads to
the recruitment of Grb2 [195]. Furthermore, FAK may be linked to
MAPK by inducing phosphorylation of its binding partner p130Cas
which in turn recruits Nck adaptor proteins [191].
At least two mechanisms have been proposed for MAPK during the
protection against apoptotic cell death. One is the MAPK-dependent
regulation of the pro-apoptotic proteins Bim and Bad. Activated
MAPK-1/2 phosphorylates Bim at several sites and this phosphorylation
targets Bim for ubiquitination and proteasomal degradation [141].
MAPK activation also speciﬁcally prevents upregulation of Bim, thus
acting both at transcriptional and posttranslational levels [150]. In addi-
tion, MAPK induces Bad phosphorylation, leading to inhibition of its
pro-apoptotic function [21,54,145,205,233]. The other mechanism by
which survival factors exploitMAPK pathway to protect against apopto-
tic cell death is the upregulation of the pro-survival members of the
Bcl-2 family, such as Bcl-2, Bcl-XL and Mcl-1, via phosphorylation of
the transcription factor cAMP responsing element binding protein
(CREB) [193].
ILK is another key player in integrin-mediated signal transduction
leading to anoikis protection. Upon cell–ECM adhesion, ILK interacts
with integrin receptors and phosphorylates its target PKB/Akt on
Ser473, thereby stimulating its activity [5,244]. Overexpression of ac-
tive FAK or ILK blocks anoikis in suspended cells, thereby supporting a
role of these kinases in anoikis protection [71,74,113,114]. Of note, ILK
conveys integrin-mediated survival signals independently of FAK, as
indicated by the inability of dominant-negative FAK to revert the
ILK-mediated protection from anoikis, suggesting that the two kinases
affect anoikis in different and parallel pathways [5,170].
Finally, another integrin-mediated survival signaling occurs
through the caveolin-1-mediated binding of integrins to the adaptor
protein Shc, which leads to a FAK-independent activation of MAPK
and consequently to escape from anoikis, as well as cell cycle progres-
sion through cyclin D1 accumulation [9,238].
Integrin engagement, besides activating pro-survival pathways
dependent on the recruitment of a platform of adaptor proteins and
kinases, can result in ligand-independent activation of many growth
Fig. 2. The molecular signature of cell survival in physiological conditions. Cell adhesion to ECM triggers several pro-survival pathways through the activation of key players (FAK,
ILK, Src, Shc), converging on master regulators of anoikis resistance, namely PI3K/Akt and ERK. These pro-survival routes promote on one hand the expression and/or activation of
anti-apoptotic proteins (Bcl-2, Bcl-XL, NF-κB) and, on the other, the inhibition of pro-survival members (Bad, Bim), thereby preventing the intrinsic pathways of cell death. Integrin
engagement also suppresses the expression of Fas, thus interfering with the activation of the extrinsic machinery. Growth factor receptors, activated both in a ligand dependent or
independent manner, collaborate with integrin in promoting cell survival. Intercellular adhesion mediated by cadherins or other cell surface molecules, activates signaling pathway
similar to those triggered by ECM-adhesion. As a consequence of metabolic and oxidative stress induced by ECM disengagement, an autophagic response sustained by the ATG pro-
teins may provide a temporary survival mechanism, giving cells the chance to survive and reattach to the matrix (see text for details).
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[159], insulin receptor [197], platelet-derived growth factor receptor
(PDGFR) [216], receptor for hepatocyte growth factor (HGF), also
named Met [236] and vascular endothelial growth factor receptor
(VEGFR) [209].
In particular, the ligand-independent phosphorylation of EGFR in re-
sponse to integrin ligation is strictly dependent by its association with
the adaptor protein p130Cas and the Src kinase [158,159]. It has been
reported that reactive oxygen species (ROS), produced through the
involvement of the small GTPase Rac-1 upon integrin engagement, are
responsible for the redox-mediated activation of Src, leading to the
ligand-independent trans-phosphorylation of EGFR. In turn, redox-
activated EGFR switches on both MAPK and PKB/Akt pathways. Both
these pro-survival signaling mediators, lead to the phosphorylation
and ubiquitin-mediated degradation of Bim, thereby preventing the
anoikis execution [89]. Conversely, in suspended cells the disengage-
ment of β1 integrin inhibits the expression of EGFR and induces Bim ac-
cumulation [202]. In addition, prolonged cell suspension further
reduces EGFR expression, thus sustaining the suppression of survival
signals, while the re-establishment of integrin-mediated adhesion res-
cues the levels of EGFR and its pro-survival spur [158].
Besides the above described signaling events initiated upon cell–
ECM attachment and leading to cell survival through the suppression
of the intrinsic pathway, the extrinsic pathway has also been shown
to be inhibited by ECM engagement. Matrix attachment protects endo-
thelial cells from the death receptor Fas-induced apoptosis by suppress-
ing the expression of Fas and an endogenous antagonist of caspase-8,
c-FLIP. Regulation of the c-FLIP expression involves MAPK activation
in an adhesion-dependent manner, although FAK does not appear to
be involved [4].3.2. Lack of adhesion during cell migration
The second physiological process in which cells need to escape
from anoikis is the temporary displacement of focal contacts during
cell migration. One of the motility style that cells use to migrate is
the mesenchymal motility, characterized by an elongated cell mor-
phology with established cell-polarity and dependent upon ECM pro-
teolysis and focal contacts [68,248]. Integrin engagement within focal
contacts and the concomitant activation of several receptor tyrosine
kinases (RTKs), including Met, which is often the initiating event for
mesenchymal motility, leads to PI3K activation and grants for the
commitment of a pro-survival signaling [12,248]. In addition, this
leads to the PI3K-dependent activation of Rac-1 and Cdc42 at the
leading edge of the cell, which coordinate actin polymerization
[187]. Mesenchymal motility is clearly linked to pro-survival signals,
as several recent reports showed for cells undergoing epithelial–mes-
enchymal transition (EMT) (see Section 4.3).
The alternative motility style is the amoeboid migration, which
allows cells to glide through, rather than degrade, ECM barriers
through a weakening of focal contacts. Intriguingly cell–ECM attach-
ments are not required for amoeboid movement and focal adhesions
are not organized [68,248]. It is likely that during amoeboid motility,
the pro-survival signals are ensured by the strong activation of the
Rho family of GTPases. In keeping with this hypothesis, RhoG has
been reported to regulate the suppression of anoikis in a PI3K-
independent manner [249].
The amoeboid movement is also exploited by non-professional ad-
hering cells, among which hematopoietic stem cells and leukocytes
[70]. T lymphocytes and other leukocytes move in a protease-
independent manner across matrix barriers through adaptation of the
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of these cells is driven by weak interactions with ECM, thereby permit-
ting high velocities. Since in hematopoietic stem cells and leukocytes
integrin-mediated focal adhesions are dispensable, they are unable to
ensure pro-survival signals. Hence, it is conceivable that these non-
adhering cells are protected from anoikis by the anti-apoptotic signal
elicited by several cytokines, including interleukin-2 (IL-2), IL-7, IL-15
and interferon-α, which selectively abrogates induction of the pro-
apoptotic BH3-only proteins [67]. In keeping with this hypothesis, in
quiescent T-cells the withdrawal of survival factors leads to Bim
accumulation and Bcl-XL downregulation and ﬁnal commitment to
apoptosis [186].
3.3. Cell–cell contacts
Increasing evidence show that not only cell–matrix adhesion but
also cell–cell adhesion supports cell survival. Cell–cell contacts are
mainlymediated by cadherins, a family of membrane proteins allowing
homotypic or heterotypic calcium-dependent cell–cell anchorage.
Cadherins play a crucial role in the complex network of survival signal-
ing. Indeed, it has been reported that blockage of E-cadherin binding
induces anoikis [17,123], while overexpression of β-catenin, a down-
stream regulator of cadherin signaling, elicits anoikis resistance in epi-
thelial cells [165]. N-cadherin signaling mainly promotes survival in a
PI3K/Akt-dependent fashion (see also Section 4.3) [17]. In addition,
cadherins may also affect cell survival through indirect association
with integrins. Indeed, some integrins, i.e. α2β1 and α3β, can be local-
ized at cell–cell contacts and canmediate survival signals despite loss of
ECM adhesion. Fascinatingly, these integrins are functionally associated
with the EGFR, suggesting a functional role of EGFR trans-activation as a
pro-survival signal [255].
Recent evidence highlight that, in addition to cadherin, intercellular
adhesion mediated by other cell surface molecules, as P- and L-selectin
and NCAM, play an important role in cell survival via the activation of
intracellular signaling molecules, similar to those triggered by ECM-
adhesion, such as FAK, Src, PI3K/Akt and MAPK [13,31,103].
3.4. Detachment-induced autophagy
On detachment from the ECM, normal epithelial cells show a sub-
stantial downregulation in EGFR expression, which results in the inhibi-
tion of the pro-survival PI3K/Akt pathway [181]. Both PI3K andAkt have
been found to be crucial for glucose transport andmetabolism [63] and,
accordingly, detached epithelial cells also show a marked reduction in
ATP levels, which is a result of the loss of glucose transport. In addition,
the impairment in glucose uptake leads to low levels of glucose-
6-phosphate and limits ﬂux through the pentose phosphate pathway
(PPP). The reduced PPP ﬂux causes an increase in reactive oxygen spe-
cies (ROS) levels, thereby further inhibiting ATP generation and contrib-
uting to the induction of cell death [34]. In this context, autophagy may
provide a temporary survival mechanism, which delay the onset of ap-
optosis, thus giving cells the chance to survive and reactivate once they
reattach to the ECM [76,108]. During autophagy, cells package cellular
proteins and organelles within the autophagosome. The vesicles are
then catabolized by lysosomes and the degraded products are utilized
by the cell in order to create new proteins. Induction of autophagy is
driven by the activation of proteins that sense cellular metabolic stress,
such as AMP activated protein kinase (AMPK) [121,146]. AMPK acti-
vates the canonical autophagic pathway through ATG6 and ATG8,
thereby sustaining ATP levels and delaying anoikis (Fig. 2) [128]. The
functional players of such integration are Beclin-1, an autophagic pro-
tein acknowledged to modulate the anti-apoptotic role of Bcl-2 and
Bcl-XL [264] and MAPKs [7]. In addition to the activation of autophagy
by metabolic stress, it has been found that autophagy can be induced
also by ECM detachment-induced oxidative stress. This oxidative
stress-mediated induction of autophagy has been found to be controlledby the activity of the RNA activated protein kinase like endoplasmic re-
ticulum kinase (PERK) [7]. In turn PERK phosphorylates and activates
eukaryotic translation initiation factor 2α, thus inducing transcription
and translation of the ATG proteins required for autophagy and sustain-
ing survival to detachment [7].
4. Anoikis resistance in cancer cells
Nevertheless non neoplastic cells undergo anoikis in response to
ECM detachment, cancer cells rapidly develop several mechanisms
to resist anoikis and exploit them to progress towards malignancy
and spread metastases to distant organs. Cancer cells can achieve re-
sistance to anoikis through: i) a speciﬁc switch in their integrins,
thereby adapting to the metastatic site, ii) undergoing to EMT,
iii) exploiting a constitutive activation of pro-survival signaling due
to intrinsic or environmental factors, as well as iv) deregulating and
adapting their metabolism, mainly through Warburg metabolism or
autophagy.
4.1. “Integrins switch”
Many experimental evidences demonstrated that both deregula-
tion of integrins and changes in their expression proﬁle can contrib-
ute to cancer cells growth or metastatic dissemination. In fact, by
changing the integrin repertoire expression, cancer cells can over-
come anoikis during both the initial phase of oncogenic transforma-
tion and metastatic colonization of other organs or tissues.
Several examples of integrins switch have been reported. In human
intestinal carcinoma cells, downregulation of αvβ3 integrin expression
protects suspended cells from death, suggesting that this contributes to
acquisition of an anoikis resistant phenotype [160]. Moreover, results
obtained from other studies demonstrated that in melanoma cells
αvβ3 integrin has a positive role in induction of anoikis resistance. In-
deed, it has been observed that integrin αvβ3 is expressed in invasive
melanoma but not in benign nevi or normal melanocytes suggesting
that αvβ3 expression is essential to promote anoikis resistance, cancer
cells invasion and metastatization [64,80]. The contribution of αvβ3
integrin in the acquisition of a anoikis-resistant/migratory cancer cell
phenotype, is also conﬁrmed by analyses of different prostate cancer
cell lines. In fact, normal prostate epithelial cells and androgen-
sensitive LNCaP prostate cancer cell line did not express αvβ3 integrin
which results otherwise expressed on androgen-resistant PC3 cancer
cell line [263].
Analysis of integrins expression proﬁle reveals that normal squa-
mous cells express prevalently α2β1, α3β1 and α6β4 integrins; on
the contrary, αvβ5 integrin, able to activate intrinsic apoptotic path-
way when unligated, is expressed at low levels. Transition from nor-
mal cells to hyperproliferative as well as cancerous phenotype, is
associated with high expression level of pro-survival αvβ6 integrin.
This switch strongly contributes to the acquisition of an anoikis-
resistant phenotype [118]. Integrin α6 expression is also signiﬁcantly
upregulated in numerous carcinomas, including head and neck can-
cers and breast cancers [77,155]. In normal cells, integrin β6 is
expressed during development from a subset of epithelial cells of kid-
ney, lung, and skin, but became undetectable in the adult normal
cells. In contrast, according to physiophatological role in the acquisi-
tion of anoikis resistance and in the invasion process, high level
expression of integrin β6 can be detected in several types of carcino-
ma cells [32]. Overexpression of the β6 subunit into poorly invasive
oral squamous cell carcinoma stimulate migration and secretion of
metalloproteinase-3 (MMP-3) that, in turn, stimulate cell invasion
[179]. On the other hand, it is well known that MMP expression pos-
itively correlates with EMT (see also Section 4.3), suggesting that
integrin β6 expression is correlated with anoikis resistance. More-
over, other mechanisms link integrins action with anoikis resistance.
For example, it has been observed that overexpression of β4 integrin
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and a strong increase of breast cancer cells invasiveness, while β4
knockdown promotes apoptosis [20].
4.2. Constitutive activation of anti-apoptotic pathways
Detached or migrating cancer cells can adopt different strategies
to compensate the loss of integrins signals and overcome anoikis.
PI3K/Akt is one the most important signaling pathway involved in
pro-survival features, as it integrates most of the signals derived
from integrins and growth factors receptors. Akt is essential to regu-
late several cellular functions such as cell survival and cell growth,
and its aberrant or constitutive activation strongly contributes to sus-
tain cancer growth [2,40,166,184,198]. Sustained pro-survival Akt ac-
tivation can be achieved as a consequence of i) overexpression or
constitutive activation of several receptor protein tyrosine kinases,
ii) activating Ras mutations, iii) loss of the phosphatase and tensin
homolog (PTEN) function via gene mutation, deletion, or promoter
methylation, iv) alteration of PI3K activity, v) ampliﬁcation of Akt
genes or overexpression. Overall, Akt activation can modulate activity
of transcription factors that control the expression of pro- and
anti-apoptotic genes or direct phosphorylation of pro-apoptotic pro-
teins, such as Bad and procaspase-9, inhibiting their function. In addi-
tion Akt activates the transcription factors that upregulate anti-
apoptotic genes such as IKK. Finally, it has been demonstrated that
Akt negatively regulates the transcription factors that promote the
expression of death genes, such as forkhead transcription factors,
FKHR, FKHRL1, and AFX [40,166,184,198,225]. Sustained Akt activa-
tion occurs also following upregulation of N-cadherin expression. It
is well known that switch from E-cadherin to N-cadherin is a com-
mon feature of cancerous epithelial cells that undergo EMT [83].
N-cadherin recruits PI3K which in turn activates Akt and induces
anoikis resistance [39]. The role of EMT in the anoikis resistance acqui-
sition, is described in details in Section 4.3.
Activation of PI3K/Akt signaling pathway is the most common
mechanism to achieve anoikis resistance in cancer cells and PTEN is
its most important negative regulator. Loss of function mutations,
downregulation or inhibition of PTEN, a very common feature of can-
cer cells, is often correlated with achievement of anoikis resistance
and malignancy [55,234]. On the contrary, overexpression of PTEN
triggers anoikis, mainly via suppression of both FAK and Akt phos-
phorylation [55].
Other mandatory elements of anoikis signaling pathways are Src
family kinases. Based on the present knowledge, it is widely accepted
that low levels of Src activity is required to maintain integrity of the
epithelium in normal tissue. On the contrary, activation of Src, Fyn
or Yes kinases leads to cell–cell contacts disassembling and induces
scattering in both normal and tumor-derived epithelial cells through
activation of integrins and FAK signaling, while deletion of fyn and src
genes is correlated with the appearance of skin architecture abnor-
malities [27]. Moreover, elevated Src activity stimulates endocytosis
of E-cadherin through activation of the E3 ubiquitin ligase or via the
Arf-6 GTPase, favoring a mesenchymal-like phenotype [8]. Overall,
these evidence suggest that Src activity enhances EMT, an event com-
monly correlated with anoikis resistance (see Section 4.3). In cancer
cells sustained Src activation leads to constitutive phosphorylation
of FAK on tyrosine 397, allowing PI3K recruitment. This, in turn, acti-
vate Akt that inhibits apoptosis by regulating various components of
the cell death machinery, including the pro-apoptotic Bim. Phosphor-
ylated FAK acts as docking site for Grb2, leading to activation of the
Ras/MAPK pathway, that in turn causes ubiquitination and degrada-
tion of Bim. Src-mediated activation of FAK enhances Bad phosphory-
lation by Akt, inhibiting caspases-2, -3, -8 and -9 and suppressing
anoikis [8,23]. Moreover, compelling studies demonstrated that acti-
vation of Src due to its cysteine oxidation plays an important role in
the induction of anoikis resistance in aggressive prostate cancersundergoing constitutive oxidative stress, mainly acting on EGF-R
pro-survival signaling [89] (see Section 4.5).
Overexpression or constitutively activation of ILK further contributes
to cancermalignancy, leading to anchorage and growth-factor indepen-
dence, anoikis resistance, invasion of surrounding tissues and metasta-
sis. In vivo, ILK is indirectly activated by PI3K, being its kinase activity
strongly increased following interaction with phosphatidylinositol
3,4,5-triphosphate (PIP3). Conversely, PTEN, by hydrolyzing PIP3 to
PIP2, contributes to downregulate ILK activity. Several evidence demon-
strate that in epithelial cells, ILK overexpression or hyperactivation
caused by PTEN loss of function or downregulation, are fundamental
to achieve the mesenchymal phenotype [30,62,262,265]. Once activat-
ed, ILK acts on several pathways, including the small GTPases Rac1
and Cdc42, inﬂuencing cell spreading and migration, myosin light
chain, thereby stimulating cell contractility and cell motility, as well as
Akt phosphorylation, sustaining cell survival. On the other hand, ILK
phosphorylates and inhibits GSK3, resulting in the stimulation of the ac-
tivator protein 1 (AP1) andβ-catenin/TCF transcription factors, which in
turn increase synthesis ofMMP-9 and cyclin D1, favoring tissue invasion
andproliferation. Finally, ILK is able to increase Snail expression, thereby
promoting EMT and anoikis resistance (see Section 4.3) [105].
An alternative mechanism to avoid anoikis consists in deregulated
expression of growth factor receptors. As above described, their activa-
tion, also achieved through autocrine signaling of growth factors, trig-
gers activation of cell survival pathways and stimulates cells migration
and invasion. The neurotrophic tyrosine kinase receptor B (TrkB), fre-
quently overexpressed in tumors, has been described as one of the
most efﬁcient in the induction of anoikis resistance [81,254]. TrkB is fre-
quently overexpressed inmany aggressive tumors and is also correlated
to development of chemoresistance in gastric and prostate carcinomas
[220,257]. Overexpression of TrkB causes changes in cells shape,
causing rounding, detachment and induction of anoikis resistance,
transforming nonmalignant cells into highly aggressive tumor cells
[60]. In addition, TrkB triggers a clear EMT through the Twist–Snail–
ZEB1 axis leading to sustained downregulating of E-cadherin expres-
sion [208]. TrkB is also active on PI3K and MAPK signaling pathways,
concurring to both EMT and anoikis insensitivity.
It is widely described that signals triggered by integrins synergize
with growth factors signaling pathways to modulate cell survival, as
well as proliferation and migration. In mammary epithelial cells, loss
of integrin-mediated adhesion leads to downregulation of EGF-R ex-
pression and inhibition of Akt and MAPK signaling, thereby leading to
Bim accumulation and to the execution of the apoptotic program.
Bypassing this anchorage requirement through growth factor receptor
overexpression or their sustained activation is a typical mechanism
adopted from cancer cells to escape from integrin control, thereby over-
coming anoikis. Indeed, overexpression of EGF and ErbB2 receptors, a
common feature of tumors, activatesMAPK signaling inducing Bimdeg-
radation and blocking anoikis [201]. In human breast cancer, high level
of Erb2B activity stimulates upregulation of α5 integrin, via the MAPK
pathway, enhancing Src activation, which leads to sustain the ligand-
independent Erb2B activation, as well as degradation of Bim, ﬁnally
conferring anoikis insensitivity [95,100,181]. In some cases EGF-R is
coupled with TGF-β1 signaling in the regulation of migratory and adhe-
sive behavior, as both factors concur to activate FAK and Akt, contribut-
ing to overcome anoikis [109,229].
Finally, also overexpression of Neuripilin-1 has been correlated to
anoikis resistance. Indeed, in pancreatic cancer cells Neuropilin-1 in-
creases MAPK signaling and expression of the anti-apoptotic regula-
tor Mcl-1, thereby enhancing survival of cancer cells in suspension
[239].
4.3. Epithelial mesenchymal transition (EMT)
Epithelial mesenchymal transition (EMT) is a physiological pro-
cess that allows epithelial cells to remodel cytoskeleton, release the
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nomenon is usually activated during wound healing, inﬂammation
or embryogenesis (Fig. 3A). EMT has also been described for cancer
cells, allowing them to detach from neighboring cells, overcoming
anoikis and to move from their primary location and invade others
tissues. During EMT cancer cells activate epigenetic pathways that
lead to the downregulation of cell–cell adhesion molecules, such asFig. 3. EMT and anoikis resistance. (A) Stimuli that contribute to trigger EMT, allowing cance
as in the anoikis resistance. Overexpression of RTKs, the change in the integrin pattern exp
PI3K/Akt signaling pathway, inhibiting apoptotic program. On one hand, Akt acts directly,
upregulation of both HIF-1 and NF-κB activities and the inhibition of GSK-3β, allowing the
in turn, repress expression of pro-apoptotic proteins (Bid, Bax, Bim) and stimulate anti-ap
of ROS production may also contribute to overcome anoikis, favoring the ligand-independen
factors. The downregulation of E-cadherin expression elicits β-catenin migration into the n
cells motility and invasion, such as c-Myc, cyclin D1, c-Jun, MMP-1 and MMP-7.E-cadherins and γ-catenin, and, at the same time, to the expression
of mesenchymal markers such as vimentin, ﬁbronectin, α-smooth
muscle actin (SMA), N-cadherin as well as to the activation of
MMPs. It is known that the ability to overcome anoikis is correlated
with the acquisition of the mesenchymal phenotype. This is possible
because most of key players involved in EMT activation are able to
modulate pro- and anti-apoptotic genes. Indeed, on one hand, theyr cells to avoid anoikis. (B) Signaling pathways involved in the induction of EMT as well
ression, downregulation of PTEN, all contribute to stimulate activation of pro-survival
favoring degradation of proapoptotic proteins, while on the other hand, Akt leads to
upregulation of Snail, ZEB1/2, Twist, and some of the master regulator of EMT. These,
optotic proteins expression (BclX/XIAP), contributing to overcome apoptosis. Increase
t activation of growth factors or the redox-mediated downregulation of pro-apoptotic
ucleus, where it stimulates the expression of target genes involved in the regulation of
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or activate pro-survival pathways (i.e. PI3K/Akt), while on the other
hand, they lead to downregulation of pro-apoptotic proteins such as
p53-effector related to pmp22 (PERP), p21, Bim, Bax and Noxa [246].
Key players involved in EMT induction are transcription factors
such as Snail, ZEB1/2, Twist, NF-kB and HIF1/2 (Fig. 3B). They are
often aberrantly expressed in cancer cells, and share the ability to de-
crease E-cadherin expression, while increasing the expression of mes-
enchymal markers. For example, Twist activation strongly contributes
to migration and invasion, as conﬁrmed by the evidence that its
downregulation reduces both processes. On the other hand, Twist pro-
motes survival, upregulating the level of anti-apoptotic Bcl-2 protein
[136,250]. Similar mechanism has been described for Snail-1, which
has found upregulated in primary human breast carcinomas and
breast tumors [19]. In particular, several spurs, including insulin-like
growth factor and hepatocyte growth factor/scatter factor, inhibit gly-
cogen synthase kinase-3β (GSK-3β), thus inducing the ubiquitin-
mediated Snail degradation. As a consequence, Snail directly represses
E-cadherin transcription as well as of other genes involved in anoikis,
such as Bid, caspase-6, or PTEN. Downregulation of PTEN leads to PI3K/
Akt pathway activation, favoring phosphorylation and inactivation of
the pro-apoptotic protein Bad, thus contributing to anoikis resistance
[11].
ZEB1 transcription factor has been associated to anchorage-
independent growth of lung cancer cells, contributing to EMT and
malignancy [82,164,219]. Again, ZEB1 expression causes an increase
of Vimentin and a decrease of E-cadherin and semaphorin 3F expres-
sion, events that contribute to activation of Akt pathway, thereby pro-
moting anoikis resistance [219].
The downregulation of E-cadherin expression promotes cytoplas-
mic accumulation of free β-catenin, which migrates into the nucleus
leading to upregulation of target genes involved in the regulation of
cells motility and invasion, such as c-Myc, cyclin D1, c-Jun, MMP-1
and -7 [196] (Fig. 3B). Overexpression or cytoplasmic stabilization
of β-catenin, due to mutations affecting its degradation, confers
anoikis resistance to cancer cells through the involvement of MAPK,
c-Myc, and cyclin D1, and maintains a stable mesenchymal pheno-
type, repressing genes of the epithelial signature [165].
Other important transcription factors contributing to anoikis resis-
tance of cancer cells are hypoxia-inducible factors (HIFs). Cancer cells
proliferate quickly, thereby generating poorly vascularized tumor
masses characterized by hypoxic or anoxic regions. The activation of
HIF-1/2 is instrumental for cancer cells to trigger the EMT program,
allowing them to escape from the hostile hypoxic milieu [126,228]. In
particular, the role of HIF1 in sustaining anoikis resistance in bothmam-
mary or prostate cancers, is mainly linked to its ability to drive EMT, by
promoting Twist or NF-kB activation and sustaining Snail expres-
sion [86,87,215]. Some evidence indicate that HIF-1 may also lead to
anoikis protection through enhanced EGFR expression, activation of
MAPK and causing degradation of pro-apoptotic proteins such as Bim
and Bmf [241]. In keeping with the key role played by HIF-1 in the reg-
ulation of metabolism of cancer cells, it has been described that
prolonged hypoxia increases the expression of several proteins in-
volved in the control of autophagy, such as BNIP3, Beclin-1 and ATG5,
suggesting that HIF-1α can alsometabolically sustain anoikis resistance
bymodulating autophagy [256]. Beside the hypoxic activation of HIF-1,
the transcription factor can also be activated independently from
decrease of oxygen, for example in response of activation of membrane
receptors. Normoxic stabilization of HIF-1 in response to ErbB2 expres-
sion by cancer cells is due to constitutive activation of Akt, able to stim-
ulate HIF-1 α and β subunits association, thereby upregulating HIF
activity in a hypoxia-independent manner. In keeping, depletion of
HIF-1α in cancer cells restores anoikis sensitivity in detached cells,
whereas does not affect cell death of ECM attached cells [143]. Of
course, sustained stimulation of several other growth factor receptors
such as EGFR, IGF-1R, stem cell factor receptor, TGF-βR and Notch,may behave similarly with respect to ErbB2, eliciting PI3K/Akt activa-
tion and enhancing HIF-1 activity, modulating the expression of EMT
and anti-apoptotic genes. Indeed, beside Snail, Twist or NF-kB, HIF-1 ac-
tivation modulate expression of other EMT effectors, such as CXC che-
mokine receptor 4 (CXCR4) and its ligand stromal derived factor-1, as
well as of stemness/pluripotency-associated transcription factors such
as Oct-3/4, Nanog and Sox-2 [156].
NF-κB is an important redox-sensitive transcription factor impli-
cated in the regulation of development, inﬂammation, cell prolifera-
tion and survival. In its inactive form NF-κB binds IκB and is
retained in the cytosol. Several stimuli can induce the phosphoryla-
tion and dissociation of IκB from NF-κB, which migrates into the
nucleus and induces expression of anti-apoptotic proteins, such as
Bcl-xL and XIAP [226]. NF-κB is constitutively activated in several
cancer type and strongly contributes to activate and maintain cancer
cells in a mesenchymal state through engagement of the EMT plat-
form [86,87,245]. Once activated, NF-κB is able to regulate anoikis re-
sistance through activation of the pro-survival PI3K/Akt signaling
pathway, repressing pro-apoptotic proteins, as well as activating
Snail-1, MMP-2 and -9, interleukin-8, vascular endothelial growth
factor and CXCR4, coupling anoikis resistance to metastasis dissemi-
nation [106,112,124].
4.4. microRNAs
MicroRNA (miR) are non coding RNA that post-translationally reg-
ulate gene expression [78]. Compelling evidence demonstrate that
several miRs are directly involved in negative EMT regulation and
acquisition of anoikis resistance, even if they can exploit different
pathways. The majority of miRs is downregulated as tumors become
less differentiated and malignancy increases, suggesting a role for
these molecules in determining cellular differentiation state and
cancer aggressiveness [91].
miR200 family is surely the most acknowledged to be involved in
the regulation of the epithelial phenotype. The family includes miR-
200a, -200b, -200c, -141 and -429. Most of these repress ZEB1/2,
upregulating E-cadherin expression and drivingmesenchymal epitheli-
al transition (MET), the reversal epigenetic plasticity adaptation with
respect to EMT [212]. On the other hand, ZEB1/2 repressmiR-200 family
expression, thus contributing to generate a negative feedback loopwith
the miR-200 family [107]. Analyses carried out on several cancer cells
highlight that downregulation of expression ofmiR200 familymembers
is strictly related to EMT (Fig. 4). For example, expression of miR200c in
breast cancer cells leads to EMT inhibition [227]. Beside its regulation of
ZEBs, miR200c acts on themodulation of TrkB, thereby inhibiting it: cell
transfection with a mutant of TrkB, insensible to miR200c regulation,
stimulate EMT, promoting anoikis resistance [111]. Finally, forced ex-
pression of miR-200c in human endometrial carcinoma cells reduces
migration, invasion and increases sensitivity to taxanes [207]. In agree-
ment with this, miR-200c has often been found downregulated in sev-
eral histotypes of cancer, allowing upregulation of several genes such
as these encoding ﬁbronectin-1, moesin, TrkB, leptin receptor and Rho
GTPase activating protein-19 [111]. The consequence of miR-200c
downregulation is the activation of signaling pathways that stimulate
cell motility, EMT and anoikis resistance [260]. Moreover, beside their
role in EMTmodulation,miR200 familymembers are also able to induce
anoikis resistance in cancer cells using different routes. Indeed, it has
been observed that in human breast cancer cells, overexpression of
miR-200a promotes anoikis resistance through the regulation of the
anti-apoptotic protein YAP1, with a clear correlation with metastasis
diffusion in patients with breast cancer [252].
Besides miR200s, other miRs have been negatively correlated to
anoikis resistance, and again their activity appear linked to EMT con-
trol (Fig. 4). For example it has been demonstrated that miR-155,
downregulating RhoA, is important to induce TGF-β mediated EMT
and anoikis resistance [131]. In addition, miR-30a has been identiﬁed
Fig. 4. Role of miRNA in the induction of anoikis resistance. Several miRNA are involved in the control of cell differentiation and their expression inhibits EMT and promotes anoikis
in detached cells. In cancer cells, their downregulation favors cell survival. For example, downregulation of miR-200a, -200b, -200c, -141 andmiR-429 stimulates expression of tran-
scription factors ZEB1/2, promoting EMT and anoikis resistance. On the other hand, decrease of miR-26 expression causes a RB1-mediated E2F1 inhibition, thereby leading to NF-κB
activation, EMT induction and contributing to anoikis resistance. On the contrary, in several cases, it has been observed that the overexpression of miRNA, more than their
downregulation, is involved in the control of EMT process. For example, the increase expression of miR-125b, as well as TGF-β-dependent expression of miR-155, leads to
downregulation of p53, which controls the expression of both miR-200 and miR-192 families, known repressors of ZEB1/2. Thus, expression of both miR-125b and miR-155 acti-
vates EMT, contributing to enhance detached cells survival. Similarly, upregulation of miR-221/222 contributes to ZEB2 expression and EMT induction; furthermore, upregulation of
miR-30a regulates EMT increasing expression of Snail. Other miRNA lead to anoikis resistance through different mechanisms. Upregulation of both mir-141 and miR-200a increases
ROS production, activating pro-survival pathways. Finally, expression of miR-21 downregulates PTEN expression, activating pro-survival PI3K/Akt signaling pathway.
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although not yet addressed [133]. Similarly, as recent studies suggest
that p53 suppression of EMT is mediated by miR200 and miR192 fam-
ily members through repression of ZEB1/2, we can speculate that
miR192 family can also be involved in the regulation of anoikis insen-
sitivity [96,129].
SomemiRNA are implicated also in the regulation of ROS production
and modulation of oxidative stress, a mandatory prerequisite for EMT
[86,87,177]. For example, it has been observed that high-grade human
ovarian adenocarcinoma cells express both miR-141 and miR-200a
and show low p38α activity and are characterized by an associated ox-
idative stress signature [152]. Compelling evidence demonstrate that in
cancer cells oxidative stress promotes EMT (see Section 4.5), thereby
suggesting that bothmiR-141 andmiR-200amay promote anoikis resis-
tance through EMT-oxidative stress mediated induction.
Overexpression of miR-221 and miR-222 protects cancer cells
from apoptotic stimuli induced by several drugs or from anoikis
after cells detachment. Both miR-221 and 222 contribute to induce
EMT by targeting the 3′ untranslated region of trichorhinophalangeal
syndrome type 1, a transcriptional repressors that inhibits EMT by re-
ducing ZEB2 expression. Thus, miR-221 and miR-222, increasing ZEB2
activity, may stimulate EMT, overcoming anoikis [214].
Beside the regulation of EMT, miRs can regulate anoikis resistance
by directly controlling pro-survival pathways. In this view, mir-21 has
been reported to target PTEN and the pro-apoptotic programmed cell
death 4 antigen (PDCD4), leading to downregulation of PTEN, stimu-
lation of Akt pathway and reducing apoptosis in cancer cells and pro-
moting cell survival [116].
miR-210 has been correlated to the transcriptional program en-
gaged by hypoxia. This miR has been found expressed in many tumors
and its contribution to inhibition of pro-apoptotic signaling in an
hypoxic environment is linked to its dependence from HIF-1 [37].
miR-155 targets the tumor protein p53 inducible nuclear protein 1
(TP53INP1), a positive regulator of p53-mediated apoptosis. Asexpected, downregulation of TP53INP1 by miR-155 attenuates apo-
ptotic pathway, promoting cell survival [93].
miR-26a is downregulated in human esophageal adenocarcinoma
cells, leading to increased Rb1 expression levels and causing E2F1 inhi-
bition, thereby inducing cell cycle arrest. As E2F1 is involved in the re-
pression of NFκB activity, the consequence of miR-26a downregulation
are both NFκB activation and anoikis suppression [260]. Moreover, in
mesenchymal stem cells, expression of miR-125b increasesMAPK phos-
phorylation and suppresses p53 expression, promoting cell survival in
response to detachment [253].
Nevertheless our understanding about the role of miRs in cellular
functions is at its infancy, their downregulation is a common feature
of cancer cells and this correlates with cancer cell plasticity and
stemness through the regulation of MET/EMT, thereby affecting can-
cer cell resistance to anoikis.4.5. Regulation of anoikis resistance due to oxidative stress or hypoxia
Compelling evidence demonstrate that in cancer cells chronic ROS
production contributes to promote cell survival, proliferation and
metastatic dissemination. External factors, such as exposition to radi-
ation, chemicals or drugs can contribute to increase of intracellular
ROS levels. Moreover, activation of cellular receptors, EMT engage-
ment and p53 inactivation may contribute to ROS production [90]
(Fig. 5).
Exposure of lung carcinoma andmelanoma cells to subtoxic doses of
hydrogen peroxide signiﬁcantly upregulates Cav-1 which, by activating
Akt pathway, leads to anoikis resistance and anchorage-independent
growth [102]. Similarly, treatment with hydrogen peroxide abrogates
anoikis commitment after cell detachment, by preventing Cav-1
downregulation [185]. Exposure of human lung carcinoma cells to
subtoxic doses of cisplatin, chronically increases intracellular ROS levels
and Cav-1 expression, leading to anoikis resistance [210].
Fig. 5. Alteration of cancer cell redox state and acquisition of anoikis resistance. Several stimuli, such as RTK overactivation, UV, radiations, drugs and xenobiotics, integrin engage-
ment, cytokines and growth factors, contribute to the increase in intracellular ROS levels. These, in turn, activate redox-sensitive transcription factors (HIF-1, NF-κB and p53) pro-
moting the increase of expression of anti-apoptotic proteins (Bcl-xL, XIAP, TRAF1 and c-FLIP), or the suppression of pro-apoptotic protein such as Bim and Bmf. Activated
transcription factors stimulate also the expression of TNFα and TGF-β1, thereby sustaining cancer cells autocrine stimulation loops. ROS inhibit PTPs, increasing pro-survival
PI3K/Akt signaling pathway, thereby leading to inhibition of pro-apoptotic pathways. In addition ROS activate Src kinase which sustains ligand-independent EGFR activation, lead-
ing to anoikis resistance. ROS mediated Nrf-2 activation allows cancer cells to control intracellular ROS levels. Once activated, Nrf-2 migrates into the nucleus and stimulates expres-
sion of several antioxidant enzymes. Overall, these mechanisms enable cancer cells to adapt to stress condition, overcoming anoikis.
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duction by activating enzymes such as NADPH oxidase (Nox) and
lipoxygenase. Most cancer cells overexpress growth factor receptors
or show autocrine behavior, producing and secreting growth factors
that sustain receptor activity and constitutive ROS production. Nota-
bly, ROS modulates activation of Akt and MAPK signaling pathways,
as well as the activity of redox-sensitive transcription factors (NF-kB,
HIF-1/2, p53, AP-1, Nrf2, etc.), thus contributing to sustain autocrine
loops [97]. It has also been observed that growth factor activation in-
creases Nox expression, contributing to maintain high levels of ROS
production [33].
Increase of ROS levels is important to achieve anoikis resistance in
cancer cells. The activity of most proteins involved in signaling path-
ways activated by both integrins and growth factor receptors are regu-
lated by reversible phosphorylation on serine, threonine or tyrosine
residues. Phosphotyrosine phosphatases are susceptible to oxidative
modiﬁcation of essential catalytic cysteine residue, thereby causing
their oxidative inhibition [46]. Several studies showed that sustained
ROS production leads to constitutive inactivation of PTEN, PTP-1B,
SHP2, LMWPTP, PP2a and PP1a enzymes. In addition, ROS promote
the activation of Src kinase and several redox sensitive transcription fac-
tors (NF-kB, HIF-1α, p53 AP-1) [168], contributing to sustain PI3K/Akt
signaling pathway and enhance cell survival through pro-apoptotic
Bad inhibition [94,171].
It has been demonstrated that in human epithelial cells ROS activate
Src kinase, which transactivates EGFR in a ligand-independent manner.
This activates bothMAPK and Akt signaling pathways, leading to degra-
dation of the pro-apoptotic protein Bim [88]. Moreover, angiopoietin-
like 4 protein interacts with β1 and β5 integrins and stimulates super-
oxide production through Nox activation, thus mimicking anchorage
conditions and bypassing anoikis by controlling ROS [222]. In addition,moderate increase of ROS leads to NF-κB activation promoting the in-
crease of expression of anti-apoptotic proteins such as Bcl-xL, XIAP,
TRAF1 and c-FLIP, the inhibition of JNK, and the upregulation of antiox-
idant genes such asMn-SOD. By these alternative pathways, cancer cells
rescue the balance of ROS levels and become insensitive to apoptosis
[125].
Constitutive oxidative stress may also affect anoikis insensitivity in
strict correlation with malignancy. Aggressive and metastatic pros-
tate cancer cells undergo a constitutive activation of 5-lipoxygenase,
sustaining increased intracellular ROS. These, in turn, oxidize and ac-
tivate Src kinase enhancing the ligand-independent EGFR activation.
In turn, sustained EGFR signaling leads to inhibition of Bad phosphor-
ylation and Bim degradation, thereby promoting cell survival even in
the absence of adhesion to ECM. Antioxidant treatment of prostatic
cancer cells completely abolishes the ligand-independent activation
of EGFR, as well as their resistance to anoikis, thus restoring the
apoptogenic stimuli [89].
Rapid growing tumors exhibit hypoxic intratumoral regions and
require a complex adaptation of cancer cells for their survival. Brieﬂy,
hypoxia activates a transcriptional response leading cancer cells to
activate i) a glycolytic metabolism sustaining survival, ii) an escaping
strategy through enhanced motility and iii) secretion of angiogenic
growth factors to reconstitute a functional vasculature. Hypoxia pro-
motes EMT in a variety of carcinoma cells, including melanoma,
breast, prostate and colon cancers [115,139]. In detached hypoxic
cells, anoikis inhibition occurs through HIF-1 dependent upregulation
of Snail and Twist and suppression of pro-apoptotic protein such as
Bim and Bmf (also see Section 4.3) [115,241]. On the other hand, it
has been observed that hypoxia leads to increase of intracellular
ROS leading to inhibition of both prolyl hydroxylase and asparagyl
hydroxylase, the most important negative regulators of HIF-1 [240].
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the expression of genes involved in cell survival, metabolism as well
as motility and invasion. At the same time ROS production contrib-
utes to inhibit GSK-3β, nuclear Snail translocation, E-cadherin
downregulation, thereby activating the EMT program and sustaining
anoikis resistance [101] (Fig. 5).
Cancer cells respond to hypoxia activating several mechanisms that
allow them to survive and even proliferate in a hypoxic environment. It
is likely that the pro-survival pathways activated during hypoxia and al-
ready linked to chemotherapy resistance in several cancer models, can
also contribute to anoikis resistance in detached hypoxic cancer cells.
The role of hypoxia in granting a pro-survival spur is clear. For example,
hypoxia protects hepatoma cells against etoposide-induced apoptosis,
downregulating p53 expression and increasing c-Jun DNA binding ac-
tivity [50,199]. Similar results has been obtained with breast cancer
cells treated with paclitaxel. In this case, hypoxia was able to increases
the expression of c-Jun and DNA binding activity of AP-1. In turn,
c-jun was able to upregulate Mcl-1 expression which participates to
the hypoxia-induced protection against apoptosis induced by paclitaxel
[66]. Severe hypoxia or anoxia leads to HIF-1-independent expression
of the anti-apoptotic protein IAP-2 that protects cells from apoptosis
[59]. Mild hypoxia protects cells prom apoptosis interfering directly
with several components of the apoptotic pathway and downregulating
the expression of nearly all the pro-apoptotic Bcl-2 family proteins, de-
creasingNoxa and Bad abundance or leading to post-translationalmod-
iﬁcation of Bim, enhancing cell survival and inducing chemoresistance
[200,241].
Several tumors also show an increased antioxidant capacity in re-
sponse to oxidative stress, suggesting that enhanced antioxidant ac-
tivity is necessary for tumor progression. To avoid anoikis triggered
by excessive ROS production, detached cancer cells are able to regu-
late expression of several antioxidant enzymes through a mechanism
that involve the transcription factor Nrf-2. Normally, Nrf-2 binds
Keap-1 and is retained therefore in the cytoplasm.When ROS concen-
tration increases over the threshold, leading to Keap-1 oxidation,
Nrf-2 dissociates from oxidized Keap-1 and migrates into the nucleus
enhancing expression of many antioxidant proteins, including heme
oxygenase-1, peroxiredoxin-1, the heavy and light chains of ferritin, cat-
alase, glutathione peroxidase, superoxide dismutase, and thioredoxin
[142]. This transcriptional control allows survival of cells in pro-
oxidantmilieu, a very common feature of tumor cells and theirmicroen-
vironment [167]. Nrf-2 has an important role in preventing cancer cells
death, as it has been identiﬁed as an inhibitor of Fas-induced apoptosis.
Growing cancer cells in the presence of glutathione, leads to inhibition
of cells death, suggesting that the anti-apoptotic effect of Nrf-2 was
through elevating intracellular glutathione levels [157]. It is interesting
to note that several oncogenes, such as Ras, Raf and Myc, may activate
the Nrf-2 pathway to protect cancer cells from the oncogene-addicted
oxidative stress [226]. In keeping, Nrf2 upregulation is important to
reduce in ECM-detached cancer cells intracellular ROS concentration
enhancing cell survival and leading to anoikis resistance [34]. This hy-
pothesis is conﬁrmed by the evidence that genetic targeting of the
Nrf-2 pathway in K-Ras overexpressing murine cells impairs prolifera-
tion and cell survival [57].
Moreover, Nrf-2 activation is not the unique mechanism allowing
cancer cells to compensate ROS production. For example, H-Ras-
transformed cells, express elevated levels of peroxiredoxin-1 and
thioredoxin peroxidase with respect to parental non tumoral cells [34].
Moreover, in melanoma cells, c-Myc exerts its pro-survival role through
upregulation of GSH production [18]. Interestingly, inhibition of manga-
nese superoxide dismutase reverts chemoresistance to taxanes [178],
suggesting that similar mechanisms may also play a role in conferring
anoikis resistance to cancer cells.
In addition ROS production is correlated to EMT [90]. For example,
it has been reported that TGF-β was shown to induce EMT via
upregulation of hydrogen peroxide and MAPK signaling, whereas bothROS production and Snail activation are requested in mammary epithe-
lial cells for MMP-3-mediated EMT [177]. Recently, it has been demon-
strated that prostate cancer cells expressing Snail undergo EMT and
displayed increased concentration of ROS. Cells treatmentwith both re-
ducing agent or MEK inhibitor partially reverts Snail-mediated EMT,
demonstrating that Snail regulates oxidative stress enzymes and in-
crease ROS-mediated EMT regulated in part byMAPK activation [10]. Fi-
nally, recent studies highlight the role of tumoral microenvironment in
the induction of oxidative stress and EMT in cancer cells. Cancer associ-
atedﬁbroblast releaseMMP-2 and -9 leading to E-cadherin cleavage and
Rac1b/cyclooxygenase-2-mediated release of ROSwhich, in turn, trigger
EMT, thereby contributing to induction of anoikis resistance [86,87].
4.6. Avoiding anoikis by modulating energetic metabolism
Recently, it has been observed that cells detachment from ECM
strongly inﬂuences metabolism of normal cells, reducing glucose up-
take, glycolytic ﬂux, mitochondrial respiration and the pentose phos-
phate pathway. The consequences of detachment from ECM are the
reduction of both intracellular ATP and NADPH concentration, reduc-
tion of fatty acid oxidation, increase of ROS production and induction
of apoptosis. ErbB2 overexpression is enough to restore glucose up-
take through PI3K/Akt pathway activation, quench ROS increasing
NADPH production, rescuing cells from anoikis [35,189]. In the last
years it has been highlighted that in cancer cells modulation of meta-
bolic pathways contribute to achieve an anoikis resistant phenotype.
Cancer cells metabolize high glucose levels through glycolysis, but
most of pyruvate obtained is transformed into lactate instead of
being oxidized in mitochondria, a phenomenon described as theWar-
burg effect. Glucose uptake reduction in response to cell matrix de-
tachment activates large kinase B1 (LKB1) which, in turn, increases
AMPK activity which modulates anoikis. Indeed, once activated,
AMPK inhibits acetyl-CoA carboxylases 1 and 2, lowering NADPH con-
sumption in fatty-acid synthesis, but increasing NADPH generation
through an alternative pathway fuelling fatty-acid oxidation. This
mechanism is essential to reduce ROS produced after matrix detach-
ment, avoiding anoikis and eliciting cancer cells to survive during
the early stages or tumorigenesis or during migration [120] (Fig. 6).
Others key players of cancer metabolic reprogramming are HIF-1,
c-Myc, PTEN, and p53. Usually HIF-1 acts promoting expression of
genes involved in the regulation of several biological processes, including
cell proliferation, angiogenesis, metabolism, immortalization, migration
but also apoptosis. The fate of cells depends on the balance of these path-
ways, leading to death or cell survival. Moreover, it has been observed
that HIF-1α is phosphorylated and stabilized also through oncogenic sig-
naling pathways involving Src, Ras, protein kinase C, and PI3K, explaining
why in cancer cells it has been often found overexpressed and activated.
Hence, HIF-1 is mandatory to deeply reprogram cancer metabolism in
terms of increase of nutrient uptake, in both hypoxic and normoxic con-
ditions. Indeed, HIF-1 stimulates expression of glucose transporter
GLUT1-3 leading to increased glucose uptake [40]. In addition, HIF-1
directly forces Warburg metabolism by transcriptional regulation of
glycolytic enzymes such as hexokinase-2, pyruvate dehydrogenase
(PDH) kinase-1 (PDK-1), lactate dehydrogenase-A and pyruvate kinase
isoform-2 (PK-M2), a low-active splice formwith respect to pyruvate ki-
nase isoform-1, which is inhibited by oxidative stress or by phosphoryla-
tion on tyrosine residue [28,58,251]. Interestingly, it has been observed
that PK-M2 hydroxylation leads to nuclear translocation and stimulates
binding and activation of HIF1α, increasing the expression of metabolic
enzymes under hypoxia, thereby originating a positive loop enhancing
Warburg effect [149]. Likewise, c-Myc upregulates GLUT1, lactate dehy-
drogenase A, hexokinase 2, phosphofructokinase and glutaminase-1, the
ﬁrst enzymeof glutaminolysis [52]. Another important key player in can-
cermetabolic reprogramming is p53, which regulates glycolysis, PPP, ox-
idative phosphorylation and glutaminolysis. In normal cells, p53 directly
inhibits glucose-6-phosphate dehydrogenase, downregulating NADPH
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upregulating expression of TIGAR and Parkin proteins, whereas stimu-
lates oxidative phosphorylation and glutaminolysis. In addition it has
been observed that p53 increases expression of PTEN and AMPK
[65,213]. Loss of function of p53 or its downregulation leads to reversion
of all above mentioned metabolic effects, stimulating uptake of glucose
and glycolysis, but decreasing mitochondrial oxidative phosphorylation
and contributing to sustain Warburg effects [153].
Compelling evidences indicate that this metabolic adaptation
meets with the necessity of cancer cells to maintain non apoptogenic
ROS levels. In the presence of ROS PK-M2 is converted in a fully inac-
tive form, behaving as a bottleneck for glycolysis and promoting
NADPH synthesis through PPP, contributing to decrease ROS levels
and leading to anoikis resistance [3]. Accordingly, it has been demon-
strated that low pyruvate kinase activity leads to increased PEP
which, in turn, inhibits trioso-phosphate isomerase, blocking glyco-
lytic ﬂux and redirecting glucose-6-P in the PPP. By this way, cells in-
crease NADPH synthesis and prevent an increase in ROS upon
activation of respiration, sustaining cancer cell survival and likely
promoting anoikis resistance [99].
Finally, it has been observed that upon detachment, human mam-
mary cells upregulate pyruvate dehydrogenase kinase 4 (PDK4) that
inhibits PDH, reducing mitochondrial respiration, lowering ATP pro-
duction and stimulating glycolytic ﬂux. PDK4 has an important role
in the induction of anoikis resistance as the stimulation of PDH activ-
ity leads to increased anoikis sensitivity and to impair metastatic po-
tential of cancer cells [122].
Of course the ability of cancer cells to exploit autophagy in response
to detachment (see Section 3.4) is strongly correlated to their metabolic
deregulation. Autophagy forces tumor cells into dormancy, allowing
them to survive hostile conditions, remaining ready to de novo repro-
grammetabolismupon environmental/nutrition improvement avoiding
death [26,211]. In keeping with this view, autophagy is regulated byFig. 6. Modulation of anoikis by metabolic pathways. Cell detachment, receptors and oncog
creasing the risk of cell death. Moreover, metabolic reprogramming contributes to inhibit ano
enzymes, PDK and PK-M2, strongly increasing the glycolytic ﬂux, but inhibiting the oxidativ
in order to reduce ROS levels, avoiding anoikis. Glucose uptake reduction in response to cel
and 2, lowering NADPH consumption in fatty-acid synthesis. This mechanism allows to hannutrient deprivation and therefore by hypoxia/ischemia, oxidative
stress, TRAIL andAMPK in several cancermodels [6,44,104,172]. In addi-
tion, several oncogenes sustains EGFR expression in cancer cells, en-
hancing antioxidant capacity, enhancing glucose uptake and fatty acid
oxidation, fuelling cells with ATP and granting survival to anoikis
[147,189]. In keeping, in breast ductal carcinoma the endoplasmic retic-
ulum kinase PERK facilitates survival of ECM-detached cells by concom-
itantly promoting autophagy, ATP production, and an antioxidant
response [7]. As a ﬁnal point, autophagy has an essential metabolic
role ensuring cancer cell survival by eliminating dysfunctional mito-
chondria, allowing Warburg metabolism [259]. Of note, autophagy is
triggered by accumulation of ROS, due to mitochondrial failure
[148,258].
5. Cancer cells exploit anoikis resistance in their long metastatic
route
Cancer progression towards malignancy consists of multiple steps
which can induce or facilitate metastatic spread of tumor cells to
distant organs and reconstitution of metastatic colonies. This “long
metastatic route” can be mainly categorized into these steps: 1) carci-
nogenesis in the primary site, 2) sustained proliferative signaling
and hyperproliferation of cancer mass, 3) generation of hypoxic
environment inside the cancer bulk, 4) sustained angiogenesis/
lymphangiogenesis to reconstitute the adequate supply of oxygen
and nutrients, 5) cross-talk with the component of the new microen-
vironment including parenchymal, stromal, endothelial and inﬂam-
matory cells, 6) migration through the extracellular matrix and
invasiveness, 7) intravasation into the bloodstream 8) cell survival in
the blood and lymphatic vessels, 9) extravasation from the circulation
into the surrounding tissues of distant organs, 10) preparation of the
metastatic niche in which cancer cells should adapt, and 11) growth
of the invading cells in the new site [137,151].ene activation, hypoxia, radiation or xenobiotic agents upregulate ROS production, in-
ikis. Oncogenes, as well as HIF-1, enhance expression of glucose transporters, glycolytic
e phosphorylation. This forces cancer cells to increase NADPH production through PPP,
l matrix detachment increases AMPK activity, which inhibits acetyl-CoA carboxylases 1
dle oxidative stress in response to matrix detachment, thereby avoiding anoikis.
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several of these steps and for this reason it becomes an attractive
pharmacological target for anti-metastatic therapies (Fig. 7).
First of all the ability of cancer cells to resist natural apoptotic
death when non adherent or adherent to improper matrix is a guar-
antee to obtain the increase in cancer mass, mainly due to sustained
autocrine secretion of cytokines and growth factors. Indeed, the in-
creased size of the mass of cancer cells grossly eliminates the interac-
tion among cancer cells and their surrounding matrix. Within the ﬁrst
phases of carcinogenesis the apoptosis inside the cancer mass is mas-
sive and it is likely that the improper or absent adhesion to ECM plays
a mandatory role in their apoptosis via anoikis. The achievement of
anoikis resistance due to genomic instability will surely sustain
survival of cancer cells, thereby enhancing malignancy. Moreover,
anoikis escaping cells also activate self-cannibalism through autopha-
gy, mainly mediated by the PERK/AMPK signaling and speciﬁcally ac-
tivated by de-adhesion and not by endoplasmic reticulum stressors,
thereby granting for luminal ﬁlling during early carcinoma progres-
sion [6]. In parallel to autophagy, cancer cells during their progression
towards malignancy are profoundly reprogrammed in their metabo-
lism, undergoing changes leading to a Warburg phenotype. Of note,
many of the metabolic changes concerningWarburg behavior are me-
diated by the same pathways allowing survival to anoikis, as Akt acti-
vation, p53 loss of function or HIF-1 stabilization [237]. For example
in breast cancer cells the detachment from ECM reprograms their me-
tabolism towards Warburg-like phenotype, leading to pyruvate ki-
nase inhibition and divergence of glucose from respiration. In
keeping with this idea, decrease of glucose respiration confers anoikis
resistance to breast cancer cells [123].
Beside decrease of cell–matrix contact, tumor progression within
the primary site is accompanied by decreased cell–cell contact and
elimination of adherens junctions among cancer cells. This process is
mainly due to the activation of EMT, leading to E-cadherin repressionFig. 7. Cancer cells exploit anoikis resistance in their long metastatic route. The cartoon ill
tumor, alongside circulation and culminating in metastatic colonization of distant organs. An
In addition, for each step of the metastatic pathway the effects of insensitivity to anoikis, asand/or cleavage and elimination of cadherin-dependent cell–cell con-
tact, as well as de novo expression of N-cadherin, which favors per se
anoikis resistance. EMT can be either due to genetic intrinsic features
of cancer cells or to interactionwith environmental cues, including hyp-
oxia or interaction with stromal cells. Indeed, cancer associated ﬁbro-
blasts have been reported to enhance EMT in cancer cells within the
primary site and increase their metastatic potential through regulation
of stem-cell traits. Besides, intratumoral hypoxia has been described as
one of the environmental factors engaging EMT, mainly acting through
stabilization of the hypoxia inducible transcription factors (either HIF-1
or HIF-2) and activation of a motogen program executed by the Met
kinase, granting for invasive escaping from the hostile hypoxic tumor
site. Of note, anoikis resistance has been clearly correlated to EMT en-
gagement and the transcriptional programs leading to EMT, through
Snail-1, Snail-2, Twist, Nf-κB ZEBs, HIF-1, HIF-2 transcription factors,
also activates pathways leading to evade anoikis by constitutively acti-
vating speciﬁc pro-survival signals. For example, Snails and ZEBs inhibit
the transcription of E-cadherin and confers apoptosis resistance by acti-
vating survival genes such as the PI3K/Akt pathway. In keeping, loss of
E-cadherin in mammary tumorigenesis models grants for anoikis resis-
tance and increased angiogenesis, thus contributing to efﬁcient meta-
static spread. Furthermore, key executors of the EMT program, like
Met proto-oncogene or Trk kinase, have also been reported to enhance
the resistance to anoikis of cancer cells, thereby conﬁrming the strict
correlation between resistance to loss of adhesion andmotility through
EMT [15]. In keepingwith the ability to confer resistance to anoikis, EMT
has also been related with resistance to both radiation and treatment
with chemical agents, in strict correlation with the acquisition of stem
and survival features [43,134]. This is related to the inactivation of
p53-mediated apoptosis, promoted by Snail-1, Slug, or Hedgehog
signaling [134].
Beside EMT another adaptation in motility style has been reported
as mandatory for cancer cells in order to metastasize: mesenchymalustrates the metastatic route run by malignant cancer cells, starting from the primary
oikis resistance emerges mainly within the primary tumor and speciﬁc causes are listed.
well as the key features, are listed.
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moving in non-stiff/rigid matrices, during selective inhibition of ma-
trix proteases or integrin-mediated adhesions and has also been cor-
related with p53 or p27 loss of function mutations, all common
events in progression of cancer towards malignancy [68,69]. Never-
theless both EMT and MAT are associated with malignancy and in-
crease in metastatic colony formation, MAT undergoing cells do not
enhance their resistance to anoikis [218]. Of note, MAT appears
more correlated with the ability of cancer cells to cross endothelial
barrier, irrespective to their ability to survive when suspended [218].
Anoikis resistance may also inﬂuence another key step of the met-
astatic process: the survival of cancer cells while they are circulating
in the bloodstream. Indeed, after intravasation in the circulatory sys-
tem, cancer cells totally lose any contact with solid tissues and should
survive in a complete absence of ECM. Of course the development of
pathways leading to anoikis resistance greatly facilitates the survival
of cancer cells and their spreading to organs even very distant from
the primary tumor site. In keeping with this idea it is noteworthy
that circulating cancer cells, commonly found in several tumors and
described as malignant cells, clearly show resistance to anoikis
[16,110]. Of note, circulating cancer cells have been shown to bring
their own soil with them when they circulate in the bloodstream. In-
deed, cancer associated ﬁbroblasts strictly associate with cancer cells,
facilitating their transendothelial migration and accompanying can-
cer cells still remaining adherent to them and favoring their survival
[61]. As cancer associated ﬁbroblasts are able to elicit EMT in cancer
cells, mainly acting through a NF-KB/HIF-1/Snail1 pathway [86,87],
it is likely that the survival spur given by associated ﬁbroblasts to cir-
culating cancer cells is mainly due to the cross-talk between EMT and
anoikis resistance pathways. In addition, it is also possible that cancer
cells exploit the matrix proteins synthesized by their associated ﬁbro-
blasts to engage pro-survival signaling. Future studies should reveal
the reason for which cells bring with them ﬁbroblasts and the identi-
ﬁcation of the molecular pathways should supply attracting pharma-
cological tools to ﬁght dissemination of metastatic colonies.
An apparent contradiction of the association between EMT and
metastasis comes from repeated observations that distant metastases
derived from primary carcinomas are largely composed of cancer cells
showing an epithelial phenotype, closely resembling that of the can-
cer cells in the primary tumor [173]. This discrepancy can be rational-
ized by the recognition that MET, the reversal of EMT, likely occurs
following micrometastasis growing, due to local selective pressure
for the outgrowth of cancer cells with more epithelial features or to
the absence of EMT-inducing signals at sites of dissemination
[173,223]. On the basis of the correlation between anoikis resistance
and EMT one could argue that metastatic colonization and the conse-
quent de novo achievement of an epithelial phenotype through MET
may be associated with sensitivity to anoikis as well. Although data
supporting this idea are still lacking, we should consider that the
new organ in which cancer cells originate the metastatic colony is
likely to contain an improper ECM for cancer cells, which should im-
pede or decrease binding of the integrins expressed by cancer cells. In
this view survival to improper adhesive stimuli is likely to be an im-
portant feature for cancer cells, irrespective by their possible MET.
An intriguing idea, still to be investigated, is that cancer cells, once
they are in the colonization site, ﬁrst exploit their resistance to anoikis
signaling and undergo MET only after their shift towards expression
of a new set of integrins that correctly bind the ECM proteins of the
new site (Fig. 7).
The ﬁnal picture that we can draw illustrates anoikis resistance as a
very useful feature for cancer cells, truly essential to obtain successful
metastases. To date, several solid data sustain anoikis resistance as an
attractive target in the ﬁght against tumor progression, but honestly
too many signaling pathways have been described to be efﬁciently
targeted by therapy. A clearer identiﬁcation of the mechanistic players
in the cellular response, as well as their exact hierarchy, may be ofhigh clinical signiﬁcance in identifying successful approaches in ﬁghting
anoikis resistance, thereby impairing metastasis.Acknowledgements
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